Key points are not available for this paper at this time.
Introduction. The world standard for treating muscle-invasive bladder cancer is radical cystectomy with pelvic lymphadenectomy. Several large studies report significant postoperative complications of radical cystectomy. In 2003, a team of urologists led by Mani Menon performed a series of robot-assisted radical cystectomies (RARC) for the first time. Currently, it is possible to evaluate the survival of patients aft er RARC. Aim. To determine the indicators of overall (OS), cancer-specific (CSS), and recurrence-free survival (RFS) aft er RARC with pelvic lymphadenectomy in patients with muscle-invasive bladder cancer that were operated at a single center. Materials and methods . In 2018–2023, 200 patients with muscle-invasive bladder cancer were operated at the Oncology Department of the Bashkir State Medical University Clinic. The operation procedure involved performing RARC with intracorporeal urinary derivation. The maximum follow-up period was limited to 36 months. The survival analysis was performed for the total cohort of patients, as well as following stratification for pN (+/–) status. In order to visualize the obtained results, Kaplan-Meier curves were used. Results and discussion. After 36 months, the survival indicators of all operated patients were as follows: OS — 48.25%; CSS — 57.49%; RFS — 61.89% ( p = 0.0031, χ 2 = 11.325). Also, a significant decrease in all the survival indicators of pN (+) patients was observed, p < 0.0001. In the pN (+) patient group, patients with advanced pT stage were found to be predominant as compared to the pN (–) group. Conclusion. The analysis of survival after RARC shows satisfactory longterm oncologic outcomes. After RARC, the leading causes of death are regional lymph node involvement and advanced pT stage.
Павлов et al. (2024) studied this question.